RESOURCES

Overcoming Challenges in the Post-PD-1 Era of Cancer Immunotherapy

Immune checkpoint inhibitors targeting PD-1 have revolutionized cancer treatment, offering durable responses in a subset of patients. However, as clinical use expands, so do the challenges, with primary and acquired resistance remaining major barriers to broader efficacy. While anti-PD1 monotherapy was initially approved for patients with high PD-L1 expression, the current landscape has shifted toward combination strategies that aim to enhance immune activation and circumvent resistance mechanisms.

Immature neutrophils promote tumor growth and metastasis through immune suppression

Neutrophils, long recognized as first responders in the immune system, are now emerging as critical players in cancer progression. Recent findings reveal that immature neutrophils not only accumulate in primary and metastatic tumors but also actively suppress anti-tumor immunity, undermining the efficacy of immunotherapies.

Unlock the Potential of Preclinical ALS Research with Advanced Mouse Models

Amyotrophic Lateral Sclerosis (ALS) remains one of the most challenging neurodegenerative diseases to study and treat, with limited therapeutic options available for patients. To bridge the gap between basic research and clinical treatment, robust, reliable, and translational animal models are essential.

Knockout All Project (KOAP): Genetically Modified Mouse Models and their Applications

Join us for an exclusive webinar exploring GemPharmatech’s ambitious Knockout All Project (KOAP), a large-scale initiative to systematically generate knockout (KO) and conditional knockout (cKO) mouse strains for all ~23,000 protein coding genes in the mouse genome.

Murine Models for Heart Failure Research

Heart failure (HF), a leading global cause of mortality, affects over 64 million people worldwide, with rising prevalence driven by aging populations and increasing comorbidities. Based on left ventricular ejection fraction (LVEF), HF is classified into two primary subtypes: HF with reduced ejection fraction (HFrEF; LVEF <40%), which is characterized by impaired systolic contraction, frequently secondary to ischemic injury; and HF with preserved ejection fraction (HFpEF; LVEF ≥50%), which is defined by diastolic dysfunction with ventricular stiffness, predominantly linked to hypertension, metabolic disorders, and aging.
Hypertrophic cardiomyopathy (HCM), a genetic disorder causing pathological left ventricular hypertrophy and diastolic impairment, represents a significant etiological contributor to both HF subtypes, particularly HFpEF.
In this webinar, GemPharmatech’s Dr. Qi Xiao will introduce diverse preclinical models developed for different applications in acceleration of therapeutic discovery.

Preclinical Strategies to Evaluate T-Cell Engagers

Targeted B-Cell Therapies: Challenges and Preclinical Evaluation Considerations for Repurposing from Oncology to Autoimmunity

While targeted therapies such as B-cell depletion and immune modulation have revolutionized treatment for B-cell malignancies, recent efforts to repurpose these therapies for autoimmune diseases, for example systemic lupus erythematosus (SLE), have gained traction. However, translating oncology-focused B-cell therapies to autoimmune diseases requires addressing fundamental differences in disease pathophysiology, therapeutic goals, and safety profiles. In this webinar, we will outline key challenges and preclinical evaluation considerations to help you navigate this cross-disciplinary transition.

Drug Resistance Models in Mice: Mechanisms, Establishment and Applications

Drug resistance remains a major obstacle to effective cancer treatments. In this webinar, we will explore how advanced preclinical models including drug resistant tumor lines and novel animal models are being leveraged to unravel resistance mechanisms. Attendees will gain insight into how these models are established, validated and applied to dissecting the molecular pathways driving resistance.

Developing Robust Preclinical Evaluation Strategies for T-Cell Engagers (TCEs): Accelerating Development and Reducing Translational Risks